D

espite widespread criticism, a new report finds the Food and Drug Administration made useful changes to a controversial program that provides access to experimental medicines. However, the agency still needs to do a better job of explaining how patient side effect data can influence drug approval decisions, according to the U.S. Government Accountability Office analysis.

Not surprisingly, the findings prompted the same sort of bickering sparked by the program, itself.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

Recommended Stories

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.